Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients

被引：1

作者：

Kraeber-Bodere, Francoise ^{[1
]}

Maisonneuve, Herve ^{[2
]}

Lamy, Thierry ^{[3
]}

Le Gouill, Steven ^{[4
]}

Deconninck, Eric ^{[5
]}

Pallardy, Amandine ^{[1
]}

Bodet-Milin, Caroline ^{[1
]}

Milpied, Noel ^{[6
]}

Morineau, Nadine ^{[7
]}

Foussard, Charles ^{[8
]}

Gastinne, Thomas ^{[4
]}

Gressin, Remy ^{[9
]}

Toumilhac, Olivier ^{[10
]}

Gyan, Emmanuel ^{[11
]}

Moreau, Anne

Chauvet, Alain Faivre ^{[1
]}

Cazeau, Anne-Laure ^{[12
]}

Garin, Etienne

Vuillez, Jean-Philippe ^{[13
]}

Chatal, Jean-Francois ^{[14
]}

Harousseau, Jean-Luc ^{[15
]}

Moreau, Philippe ^{[4
]}

Wegener, William ^{[16
]}

Goldenberg, David ^{[17
]}

Soubeyran, Pierre ^{[18
]}

机构：

[1] CHU Nantes, Nucl Med Serv, F-44035 Nantes 01, France

[2] CH La Roche Yon, La Roche Sur Yon, France

[3] CHU Rennes, Hematol Dept, Rennes, France

[4] CHU Nantes, Hematol Dept, F-44035 Nantes 01, France

[5] Hop Jean Minjoz, F-25030 Besancon, France

[6] Hop Haut Leveque, Pessac, France

[7] Ctr Catherine Sienne, Nantes, France

[8] CHU Angers, Serv Malad Sang, Angers, France

[9] CHU Grenoble, INSERM, Inst Albert Bonniot, U823, F-38043 Grenoble, France

[10] CHU Clermont Ferrand, Serv Hematol Adultes & Therapie Cellulaire, Clermont Ferrand, France

[11] CHRU Tours, Serv Hematol & Therapie Cellulaire, Tours, France

[12] Inst Bergonie, Nucl Med Serv, Bordeaux, France

[13] CHU Michallon, Nucl Med Serv, Grenoble, France

[14] GIP ARRONAX, St Herblain, France

[15] Rene Gauducheau Canc Ctr, St Herblain, France

[16] Immunomed Inc, Clin Res, Morris Plains, NJ USA

[17] Ctr Mol Med & Immunol, Belleville, NJ USA

[18] Inst Bergonie, Bordeaux, France

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

10.1182/blood.V116.21.2875.2875

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1184 / 1184

页数：1

共 48 条

[41] Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients
Zinzani, Pier Luigi
Rossi, Giuseppe
Franceschetti, Silvia
Botto, Barbara
Di Rocco, Alice
Cabras, Maria Giuseppina
Petti, Maria Concetta
Stefoni, Vittorio
Broccoli, Alessandro
Fanti, Stefano
Pellegrini, Cinzia
Montini, Gian Carlo
Gandolfi, Letizia
Derenzini, Enrico
Argnani, Lisa
Fina, Mariapaola
Tucci, Alessandra
Bottelli, Chiara
Pileri, Stefano
Baccarani, Michele
CLINICAL CANCER RESEARCH, 2010, 16 (15) : 3998 - 4004
[42] Short-course R-CHOP followed by 90Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results
Stefoni, V.
Casadei, B.
Bottelli, C.
Gaidano, G.
Ciochetto, C.
Cabras, M. G.
Ansuinelli, M.
Argnani, L.
Broccoli, A.
Gandolfi, L.
Pellegrini, C.
Zinzani, P. L.
BLOOD CANCER JOURNAL, 2016, 6 : e425 - e425
[43] Short-course R-CHOP followed by 90Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results
V Stefoni
B Casadei
C Bottelli
G Gaidano
C Ciochetto
M G Cabras
M Ansuinelli
L Argnani
A Broccoli
L Gandolfi
C Pellegrini
P L Zinzani
Blood Cancer Journal, 2016, 6 : e425 - e425
[44] SHORT-COURSE R-CHOP FOLLOWED BY (90)Y-IBRITUMOMAB TIUXETAN IN PREVIOUSLY UNTREATED HIGH-RISK ELDERLY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: 7-YEARS LONG-TERM RESULTS
Stefoni, V.
Casadei, B.
Bottelli, C.
Rossi, G.
Gaidano, G.
Ciochetto, C.
Cabras, M. G.
Ansuinelli, M.
Argnani, L.
Derenzini, E.
Broccoli, A.
Gandolfi, L.
Quirini, F.
Tonialini, L.
Pellegrin, C.
Cavo, M.
Zinzani, P. L.
HAEMATOLOGICA, 2015, 100 : 91 - 91
[45] A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization
Lopez-Guillermo, Armando
Canales, Miguel A.
Dlouhy, Ivan
Briones, Javier
Caballero, Dolores
Sancho, Juan Manuel, Sr.
Vilchez, Santiago Mercadal
Moraleda, Jose Maria
Terol, Maria Jose
Salar, Antonio
Palomera, Luis
Gardella, Santiago
Jarque, Isidro
Ferrer, Secundino
Bargay, Joan
Lopez, Andres
Panizo, Carlos
Muntanola, Anna
Montalban, Carlos
Conde, Eulogio
Hernandez, Miguel
Soler, Alfons
Marin, Julian
Marco, Jose Garcia
Deben, Guillermo
Tomas, Jose Francisco
BLOOD, 2013, 122 (21)
[46] Study of AUTO3, the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22, Followed By Anti-PD1 Consolidation in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Alexander Study
Ardeshna, Kirit
Marzolini, Maria A. V.
Osborne, Wendy
Al-Hajj, Muhammad
Thomas, Simon
Faulkner, Jim
Pule, Martin
Peddareddigari, Vijay G. R.
Khokhar, Nushmia Z.
BLOOD, 2018, 132
[47] A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Lopez-Guillermo, Armando
Canales, Miguel Angel
Dlouhy, Ivan
Mercadal, Santiago
Briones, Javier
Martin Garcia-Sancho, Alejandro
Sancho, Juan Manuel
Maria Moraleda, Jose
Terol, Maria Jose
Salar, Antonio
Palomera, Luis
Gardella, Santiago
Jarque, Isidro
Ferrer, Secundino
Bargay, Joan
Lopez, Andres
Panizo, Carlos
Muntanola, Anna
Montalban, Carlos
Conde, Eulogio
Hernandez, Miguel T.
Soler, Alfons
Garcia Marco, Jose A.
Deben, Guillermo
Marin, Julian
Tomas, Jose Francisco
LEUKEMIA & LYMPHOMA, 2022, 63 (01) : 93 - 100
[48] Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and 111In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma
Juweid, ME
Stadtmauer, E
Hajjar, G
Sharkey, RM
Suleiman, S
Luger, S
Swayne, LC
Alavi, A
Goldenberg, DM
CLINICAL CANCER RESEARCH, 1999, 5 (10) : 3292S - 3303S

← 1 2 3 4 5 →